A Suggested Modification to FIGO Stage IV Epithelial Ovarian Cancer

被引:5
作者
Metairie, Marie [1 ]
Benoit, Louise [1 ,2 ]
Koual, Meriem [1 ,2 ]
Bentivegna, Enrica [1 ]
Wohrer, Henri [1 ]
Bolze, Pierre-Adrien [3 ]
Kerbage, Yohan [4 ]
Raimond, Emilie [5 ]
Akladios, Cherif [6 ]
Carcopino, Xavier [7 ]
Canlorbe, Geoffroy [8 ,9 ,10 ]
Uzan, Jennifer [11 ]
Lavoue, Vincent [12 ]
Mimoun, Camille [13 ]
Huchon, Cyrille [13 ,16 ]
Koskas, Martin [14 ]
Costaz, Helene [15 ]
Margueritte, Francois [16 ]
Dabi, Yohann [17 ]
Touboul, Cyril [17 ]
Bendifallah, Sofiane [17 ]
Ouldamer, Lobna [15 ,18 ]
Delanoy, Nicolas [19 ]
Nguyen-Xuan, Huyen-Thu [1 ]
Bats, Anne-Sophie [1 ,20 ,21 ]
Azais, Henri [1 ,20 ,21 ]
机构
[1] Hop Europeen Georges Pompidou, Assistance Publ Hop Paris AP HP, Dept Gynaecol Oncol & Breast Surg, F-75015 Paris, France
[2] Univ Paris Cite, Ctr Univ St Peres, INSERM UMR S 1124, F-75006 Paris, France
[3] Univ Lyon 1, Lyon Sud Univ Hosp, Dept Gynaecol & Oncol Surg & Obstet, Hosp Civils Lyon, F-69002 Lyon, France
[4] Univ Lille, Dept Gynaecol Surg, CHU Lille, F-59000 Lille, France
[5] Inst Alix Champagne Univ Hosp, Dept Obstet & Gynaecol, F-51100 Reims, France
[6] Hop Univ Strasbourg, Dept Gynaecol, F-67200 Strasbourg, France
[7] Aix Marseille Univ AMU, Univ Avignon, Hop Nord, Dept Obstet & Gynaecol, F-13397 Marseille, France
[8] Pitie Salpetriere, Assistance Publ Hop Paris AP HP, Dept Gynaecol & Breast Surg & Oncol, F-75013 Paris, France
[9] Sorbonne Univ, Ctr Rech St Antoine CRSA, Canc Biol & Therapeut, INSERM UMR S 938, F-75012 Paris, France
[10] Sorbonne Univ, Univ Inst Canc, F-75013 Paris, France
[11] Univ Paris Est Creteil, Ctr Hosp Intercommunal Creteil, Dept Obstet Gynecol & Reprod Med, F-94000 Creteil, France
[12] Univ Rennes 1, Hop Sud, Dept Gynaecol Surg, equipe 8, F-35000 Rennes, France
[13] Univ Paris, Hop Lariboisiere, Dept Gynaecol Oncol & Breast Surg, F-75010 Paris, France
[14] Hop Xavier Bichat, Assistance Publ Hop Paris AP HP, Div Gynaecol Oncol, F-75018 Paris, France
[15] Georges Francois Leclerc Ctr, Dept Surg Oncol, F-21000 Dijon, France
[16] Ctr Hosp Intercommunal Poissy St Germain en laye, Dept Gynaecol, Site Hosp Poissy, F-78498 Poissy, France
[17] Hop Tenon, AP HP Assistance Publ Hop Paris, Dept Gynaecol ans Obstet, F-75020 Paris, France
[18] Hop Univ Tours, Dept Gynaecol, F-37000 Tours, France
[19] Hop Europeen Georges Pompidou, AP HP Assistance Publ Hop Paris, Dept Med Oncol, F-75015 Paris, France
[20] Univ Paris Cite, Ctr Rech Cordeliers, INSERM UMR S 1147, F-75006 Paris, France
[21] Inst Canc Paris CARPEM, F-75006 Paris, France
关键词
epithelial ovarian cancer; FIGO stage IV; metastatic patterns; prognosis; pleural involvement; overall survival; FALLOPIAN-TUBE; CLASSIFICATION; SURVIVAL; DISEASE; IMPACT; RECOMMENDATIONS; CYTOREDUCTION; COMPLICATIONS; METASTASES; PATHOLOGY;
D O I
10.3390/cancers15030706
中图分类号
R73 [肿瘤学];
学科分类号
100214 ;
摘要
Simple Summary The identification of prognostic factors is important to improve the management of patients with ovarian cancer (OC). The staging classification of OC was revised in 2014 and 2018 by the FIGO (International Federation of Gynecology and Obstetrics) Gynecological Oncology Committee and dichotomizes stages IV into stage IVA and IVB. The FIGO classification aims to establish a disease severity scale and to group patients with similar prognoses. The objective of our retrospective, multicenter study was to assess the prognostic impact of this dichotomization and of the initial metastatic localization of patients with FIGO stage IV OC. We showed that, among our 307 patients, FIGO stage IVA patients had a worse prognosis than FIGO stage IVB patients. The initial pleural effusion was a factor of poor prognosis in terms of overall survival. We suggest a modification of the current FIGO staging classification. International Federation of Gynecology and Obstetrics (FIGO) staging classification for stage IV epithelial ovarian cancer (EOC) separates stages IVA (pleural effusion) and IVB (parenchymal and/or extra-abdominal lymph node metastases). We aimed to evaluate its prognostic impact and to compare survival according to the initial metastatic location. We conducted a multicenter study between 2000 and 2020, including patients with a FIGO stage IV EOC. Primary endpoint was overall survival (OS). The secondary endpoints were progression-free survival (PFS) and recurrence rates. We included 307 patients: 98 (32%) had FIGO stage IVA and 209 (68%) had FIGO stage IVB. The median OS and PFS of stage IVA patients were significantly lower than those of stage IVB patients (31 versus 45 months (p = 0.02) and 18 versus 25 months (p = 0.01), respectively). Recurrence rate was higher in stage IVA than IVB patients (65% versus 47% (p = 0.004)). Initial pleural involvement was a poor prognostic factor with a median OS of 35 months versus 49 months for patients without initial pleural involvement (p = 0.024). Patients with FIGO stage IVA had a worse prognosis than patients with FIGO stage IVB EOC. Pleural involvement appears to be relevant for predicting survival. We suggest a modification of the current FIGO staging classification.
引用
收藏
页数:12
相关论文
共 50 条
  • [31] Interval Debulking Surgery in Patients with Federation of Gynecology and Obstetrics (FIGO) Stage IIIC and IV Ovarian Cancer
    Keyver-Paik, Mignon-Denise
    Zivanovic, Oliver
    Rudlowski, Christian
    Hoeller, Tobias
    Wolfgarten, Matthias
    Kuebler, Kirsten
    Schroeder, Lars
    Mallmann, Michael
    Poelcher, Martin
    Kuhn, Walther
    ONKOLOGIE, 2013, 36 (06): : 324 - 332
  • [32] Video-assisted thoracic surgery (VATS) evaluation of intrathoracic disease in patients with FIGO III and IV stage ovarian cancer
    Klar, M.
    Farthmann, J.
    Bossart, M.
    Stremmel, C.
    Gitsch, G.
    Passlick, B.
    Pache, G.
    Woll, J.
    Hasenburg, A.
    GYNECOLOGIC ONCOLOGY, 2012, 126 (03) : 397 - 402
  • [33] Prognostic Value of Residual Tumor Size in Patients With Epithelial Ovarian Cancer FIGO Stages IIA-IV Analysis of the OVCAD Data
    Polterauer, Stephan
    Vergote, Ignace
    Concin, Nicole
    Braicu, Ioana
    Chekerov, Radoslav
    Mahner, Sven
    Woelber, Linn
    Cadron, Isabelle
    Van Gorp, Toon
    Zeillinger, Robert
    Castillo-Tong, Dan Cacsire
    Sehouli, Jalid
    INTERNATIONAL JOURNAL OF GYNECOLOGICAL CANCER, 2012, 22 (03) : 380 - 385
  • [34] Abdominopelvic cytoreduction rates and recurrence sites in stage IV ovarian cancer: Is there a case for thoracic cytoreduction?
    Perri, Tamar
    Ben-Baruch, Gilad
    Kalfon, Sarit
    Beiner, Mario E.
    Helpman, Limor
    Hogen, Liat Ben-David
    Shapira-Frommer, Ronnie
    Korach, Jacob
    GYNECOLOGIC ONCOLOGY, 2013, 131 (01) : 27 - 31
  • [35] Neoadjuvant chemotherapy (NACT) is an effective way of managing elderly women with advanced stage ovarian cancer (FIGO Stage IIIC and IV)
    Glasgow, Michelle A.
    Yu, Herbert
    Rutherford, Thomas J.
    Azodi, Masoud
    Silasi, Dan-Arin
    Santin, Alessandro D.
    Schwartz, Peter E.
    JOURNAL OF SURGICAL ONCOLOGY, 2013, 107 (02) : 195 - 200
  • [36] Therapeutic value of selective lymphadenectomy in interval debulking surgery for stage IIIc and IV epithelial ovarian cancer
    Song, Nan
    Gao, Yunong
    INTERNATIONAL JOURNAL OF GYNECOLOGICAL CANCER, 2019, 29 (04) : 761 - 767
  • [37] Optimal cytoreductive surgery is an independent prognostic indicator in stage IV epithelial ovarian cancer with hepatic metastases
    Naik, R
    Nordin, A
    Cross, PA
    Hemming, D
    Lopes, AD
    Monaghan, JM
    GYNECOLOGIC ONCOLOGY, 2000, 78 (02) : 171 - 175
  • [38] The role of factor XIII in surgery for advanced stage of epithelial ovarian cancer
    Yazdian, Mahtab
    Groeben, Harald
    Ataseven, Beyhan
    Schneider, Stephanie
    Baert, Thais
    Bommert, Mareike
    Traut, Alexander
    Elfers-Wassenhoven, Alexandra
    Bruess, Ulrich
    Schwameis, Richard
    du Bois, Andreas
    Wagner, Uwe
    Harter, Philipp
    ARCHIVES OF GYNECOLOGY AND OBSTETRICS, 2022, 305 (05) : 1311 - 1318
  • [39] Early ovarian cancer (FIGO stage I-IIA)
    Petru, E.
    Benedicic, C.
    Kimmig, R.
    Marth, C.
    ONKOLOGE, 2008, 14 (11): : 1130 - +
  • [40] Maximal Cytoreduction in Patients With FIGO Stage IIIC to Stage IV Ovarian, Fallopian, and Peritoneal Cancer in Day-to-Day Practice A Retrospective French Multicentric Study
    Luyckx, Mathieu
    Leblanc, Eric
    Filleron, Thomas
    Morice, Philippe
    Darai, Emile
    Classe, Jean-Marc
    Ferron, Gwenael
    Stoeckle, Eberhard
    Pomel, Christophe
    Vinet, Benedicte
    Chereau, Elisabeth
    Bergzoll, Cecile
    Querleu, Denis
    INTERNATIONAL JOURNAL OF GYNECOLOGICAL CANCER, 2012, 22 (08) : 1337 - 1343